Beigene, Ltd. (NASDAQ:ONC - Get Free Report)'s share price gapped down prior to trading on Monday . The stock had previously closed at $231.99, but opened at $219.28. Beigene shares last traded at $233.00, with a volume of 113,309 shares traded.
Analyst Upgrades and Downgrades
ONC has been the topic of several analyst reports. Guggenheim upped their price objective on Beigene from $348.00 to $350.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Royal Bank of Canada lowered their price target on Beigene from $312.00 to $311.00 and set an "outperform" rating on the stock in a report on Thursday, May 8th. Macquarie raised their target price on Beigene from $259.00 to $313.00 and gave the stock an "outperform" rating in a report on Friday, February 28th. Sanford C. Bernstein set a $259.00 target price on Beigene in a report on Thursday, March 13th. Finally, JMP Securities set a $348.00 price target on Beigene in a report on Friday, February 28th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $319.00.
Read Our Latest Analysis on Beigene
Beigene Stock Performance
The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.72 and a current ratio of 1.93. The business's 50 day moving average price is $243.42. The stock has a market cap of $22.62 billion, a price-to-earnings ratio of -27.72, a PEG ratio of 7.73 and a beta of 0.35.
Beigene (NASDAQ:ONC - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $1.93. The business had revenue of $1.12 billion during the quarter, compared to analysts' expectations of $1.12 billion. Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. As a group, research analysts predict that Beigene, Ltd. will post -5.82 earnings per share for the current fiscal year.
Insider Buying and Selling at Beigene
In related news, insider Xiaodong Wang sold 41,760 shares of the stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $223.50, for a total value of $9,333,360.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Xiaobin Wu sold 51,921 shares of the stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $281.40, for a total value of $14,610,569.40. The disclosure for this sale can be found here. Insiders sold 1,187,808 shares of company stock valued at $304,531,660 over the last quarter. 6.62% of the stock is currently owned by insiders.
About Beigene
(
Get Free Report)
BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
Further Reading
Before you consider Beigene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beigene wasn't on the list.
While Beigene currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
